» Articles » PMID: 38491173

Prognostic Factors of Renal Cell Cancer in Elderly Patients: a Population-based Cohort Study

Overview
Journal Sci Rep
Specialty Science
Date 2024 Mar 16
PMID 38491173
Authors
Affiliations
Soon will be listed here.
Abstract

Mortality in renal cell cancer (RCC) is high in the elderly population. Comorbidities have a greater impact on overall prognosis of RCC among elderly patients than in younger patients. All new RCC cases were collected in people over 74 years of age between 1995 and 2018 from the Finnish cancer registry. The comorbidities were identified from the Care Registry for Healthcare. Charlson Comorbidity Index (CCI) was used to evaluate the risk of death based on comorbidities. The overall risk of death was analyzed using the Cox regression model. The risk for RCC death was analyzed using Fine and Gray regression analysis. Individual prognostic role of CCI components was evaluated by adding each component separately into the multivariable Fine and Gray regression model. Using the most prognostic comorbidities we constructed a nomogram to predict RCC mortality. Statistically significant prognostic factors of RCC death were tumor morphology (clear cell, papillary and chromophobe), sex, operative treatment, age, primary tumor extent and CCI. The strongest prognostic factors for overall mortality were tumor extent, tumor morphology and operative treatment. Among the components of CCI, the most important comorbidities predicting mortality were dementia, heart failure and kidney disease. The limitation of this study is that the comorbidities have only been recorded at inpatient and outpatient hospital contacts, which is why the prevalence of comorbidities is probably underestimated. In addition, physical performance status was not available from registry data, but it significantly affects the treatment decisions. RCC mortality is high in the elderly population. Among comorbidities, dementia and heart failure have the greatest impact on the prognosis. Curative treatment in selected elderly patients is efficient and should be considered in patients who can tolerate it and have only limited comorbidities.

Citing Articles

Up-regulation of Cuproptosis-related lncRNAS in Patients Receiving Immunotherapy for Metastatic Clear Cell Renal Cell Carcinoma Indicates Progressive Disease.

Katifelis H, Grammatikaki S, Zakopoulou R, Bamias A, Karamouzis M, Stravodimos K In Vivo. 2024; 39(1):146-151.

PMID: 39740865 PMC: 11705156. DOI: 10.21873/invivo.13812.


Stereotactic Body Radiotherapy (SBRT) for the Treatment of Primary Localized Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.

Suleja A, Bilski M, Laukhtina E, Fazekas T, Matsukawa A, Tsuboi I Cancers (Basel). 2024; 16(19).

PMID: 39409897 PMC: 11475739. DOI: 10.3390/cancers16193276.

References
1.
Horsbol T, Dalton S, Christensen J, Petersen A, Azawi N, Donskov F . Impact of comorbidity on renal cell carcinoma prognosis: a nationwide cohort study. Acta Oncol. 2021; 61(1):58-63. DOI: 10.1080/0284186X.2021.2005255. View

2.
Patel H, Kates M, Pierorazio P, Gorin M, Jayram G, Ball M . Comorbidities and causes of death in the management of localized T1a kidney cancer. Int J Urol. 2014; 21(11):1086-92. DOI: 10.1111/iju.12527. View

3.
Bai H, Jiang W, Wang D, Shou J, Li C, Xing N . Efficacy and safety of surgery in renal carcinoma patients 75 years and older: a retrospective analysis. BMC Urol. 2022; 22(1):135. PMC: 9422093. DOI: 10.1186/s12894-022-01088-3. View

4.
Capitanio U, Bensalah K, Bex A, Boorjian S, Bray F, Coleman J . Epidemiology of Renal Cell Carcinoma. Eur Urol. 2018; 75(1):74-84. PMC: 8397918. DOI: 10.1016/j.eururo.2018.08.036. View

5.
Iasonos A, Schrag D, Raj G, Panageas K . How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008; 26(8):1364-70. DOI: 10.1200/JCO.2007.12.9791. View